Literature DB >> 15983811

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.

Masaru Takeuchi1, Hideyuki Hokama, Rintaroh Tsukahara, Takeshi Kezuka, Hiroshi Goto, Jun-Ichi Sakai, Masahiko Usui.   

Abstract

PURPOSE: The purpose of the study was to determine factors correlated with the progression of irreversible visual disturbance in Behcet's disease (BD) with ocular involvement.
METHODS: Forty-seven BD patients with ocular inflammation, who presented with the first ocular episode, and who had been followed continuously for 5-10 years in our hospital, were studied. Charts were reviewed for gender, onset age of uveitis, complete or incomplete type BD, HLA-B51 status, final visual acuity at the last remission period, mean number of ocular attacks per year, and clinical findings of iridocyclitis with profuse hypopyon, strong vitreous opacity blocking the observation of retinal vessels, diffuse retinal vasculitis, and exudates with hemorrhage within the retinal vascular arcade.
RESULTS: Patients with a visual acuity of < or =20/200 and those with >20/200 differed significantly in the mean number of ocular attacks per year and clinical findings of strong vitreous opacity and exudates within the retinal vascular arcade, but not with regard to the other factors. In addition, the frequency of ocular attacks showed a significant negative correlation with the outcome of visual acuity. Logistic regression analysis indicated a significant association of an average of more than three ocular attacks per year, strong vitreous opacity, and exudates within the retinal vascular arcade with poor visual outcome.
CONCLUSIONS: This study indicates that more than three ocular attacks per year, strong vitreous opacity, and exudates within the retinal vascular arcade are the risk and prognostic factors for a poor outcome of visual acuity in BD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983811     DOI: 10.1007/s00417-005-0005-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

Review 1.  Immunopathogenesis and prevention of uveitis with the Behçet's disease-specific peptide linked to cholera toxin B.

Authors:  T Lehner; M R Stanford; P A Phipps; J B Sun; B G Xiao; J Holmgren; T Shinnick; A Hasan; Y Mizushima
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

2.  High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease.

Authors:  H H Tessler; T Jennings
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

3.  Identification of alpha-tropomyosin as a target self-antigen in Behçet's syndrome.

Authors:  Felix Mor; Abraham Weinberger; Irun R Cohen
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

4.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors:  K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

5.  Human S-antigen determinant recognition in uveitis.

Authors:  M D de Smet; G Bitar; S Mainigi; R B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

6.  Auto-oxidative damage in Behçet's disease--endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils.

Authors:  Y Niwa; S Miyake; T Sakane; M Shingu; M Yokoyama
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

Review 7.  Behçet's disease.

Authors:  R C Wong; C N Ellis; L A Diaz
Journal:  Int J Dermatol       Date:  1984 Jan-Feb       Impact factor: 2.736

8.  Comparison of patients with Behçet's disease in the 1980s and 1990s.

Authors:  Atsushi Yoshida; Hidetoshi Kawashima; Yuta Motoyama; Hirobumi Shibui; Toshikatsu Kaburaki; Kazuyuki Shimizu; Kazuhiko Ando; Kiyono Hijikata; Yasuho Izawa; Kiyofumi Hayashi; Jiro Numaga; Yujiro Fujino; Kanjiro Masuda; Makoto Araie
Journal:  Ophthalmology       Date:  2004-04       Impact factor: 12.079

Review 9.  The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects.

Authors:  S Mishima; K Masuda; Y Izawa; M Mochizuki; K Namba
Journal:  Trans Am Ophthalmol Soc       Date:  1979

10.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Authors:  Cem Evereklioglu; Hamdi Er; Yusuf Türköz; Mustafa Cekmen
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  22 in total

1.  Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis.

Authors:  Allison R Loh; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2010-10       Impact factor: 5.258

2.  Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease.

Authors:  Sho Ueda; Mitsuteru Akahoshi; Atsunobu Takeda; Yasushi Inoue; Aya Omoto; Masahiro Ayano; Yasutaka Kimoto; Hiroki Mitoma; Yojiro Arinobu; Hiroaki Niiro; Hiroshi Tsukamoto; Takahiko Horiuchi; Shin-Ichi Hikita; Takako Fukuhara; Tatsuro Ishibashi; Koh-Hei Sonoda; Koichi Akashi
Journal:  Eur J Rheumatol       Date:  2018-03

3.  Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Authors:  Tatsushi Kawaguchi; Yuko Kawazoe; Koju Kamoi; Masaru Miyanaga; Hiroshi Takase; Sunao Sugita; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

4.  Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis.

Authors:  Ilknur Tugal-Tutkun; Kürsat Cingü; Nur Kir; Baris Yeniad; Meri Urgancioglu; Ahmet Gül
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-27       Impact factor: 3.117

5.  Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease.

Authors:  Toshikatsu Kaburaki; Fumiyuki Araki; Mitsuko Takamoto; Kimiko Okinaga; Atsushi Yoshida; Jiro Numaga; Yujiro Fujino; Hidetoshi Kawashima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-08       Impact factor: 3.117

6.  Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system.

Authors:  Hae Min Kang; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-07       Impact factor: 3.117

Review 7.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

8.  Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; C Stephen Foster
Journal:  Am J Ophthalmol       Date:  2008-08-16       Impact factor: 5.258

9.  Ocular features of Behcet's disease: an international collaborative study.

Authors:  Nobuyoshi Kitaichi; Akiko Miyazaki; Daiju Iwata; Shigeaki Ohno; Miles R Stanford; Hormoz Chams
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

10.  Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease.

Authors:  Akihiko Umazume; Takeshi Kezuka; Yoshihiko Usui; Jun Suzuki; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2018-03-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.